Genomic-oriented Multi-level Regulatory Landscape of Renal Tumor Metastasis- Related Key Genes

Author:

Zhou Bin1,Wang Haiyan2,Liu Bo1,wang Zhe3,zhou Guixia1,Zhao Tingting4,Du Chunlei5,Hu Changdong6,Li Xiangping7,Ban Bo8,Guo Rui9

Affiliation:

1. Jining Medical University

2. Binzhou University

3. The first hospital of Shanxi Medical University

4. Shanxi Traditional Chinese Medicine Hospital

5. People’s Hospital of Si Shui County

6. Dehong People’s Hospital

7. Shanxi Bethune Hospital

8. Affiliated Hospital of Jining Medical University, Jining Medical University

9. Shanxi Medical University

Abstract

Abstract Metastasis of renal tumor leads to poor prognosis of patients and increased therapeutic challenges. Nevertheless, the molecular mechanism underlying this clinical phenomenon remain to be elucidated. In this study, we identified 81 metastasis-related key genes and systematically explored their regulatory axis in renal tumor metastasis. In detail, both copy number variation and DNA methylation can partially affect the expressions of these key genes and showed differential distribution in the metastatic group. Path analysis modeling evaluated the potential overall causal effects from genomic level to phenotype and determined five statistical models. Additionally, the competing endogenous network revealed the post-transcriptional regulation of these key genes. Besides that, immune cell infiltration analyses suggested that some key genes may be involve in the regulation of tumor immunologic microenvironment. Furthermore, we built an effective machine learning model to predict renal tumor metastasis for clinical application. In summary, our research systematically described the potential biological roles and regulatory profiles of renal tumor metastasis-related genes, which may contribute to the improvement of clinical targeted therapy for renal tumor.

Publisher

Research Square Platform LLC

Reference35 articles.

1. Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information system;Sun R;Can Urol Assoc J,2021

2. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma;Choueiri TK;N Engl J Med,2021

3. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma;Motzer R;N Engl J Med,2021

4. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma;Motzer RJ;N Engl J Med,2019

5. Investigators, Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma;Rini BI;N Engl J Med,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3